Es Follow Pubertal Suppression Monitoring

---
name: es-follow-pubertal-suppression-monitoring
description: Provides a monitoring schedule for patients receiving GnRH agonist therapy for pubertal suppression. Trigger phrases include 'patient undergoing GnRH agonist therapy' or 'initiating pubertal suppression'.
---

# Follow monitoring protocol during pubertal suppression

## STEP 1 — Gather Information
Collect baseline and follow-up data: every 3–6 months measure height, weight, sitting height, blood pressure, and Tanner stages; every 6–12 months obtain LH, FSH, estradiol/testosterone, and 25OH vitamin D; every 1–2 years perform DXA bone density and left-hand X-ray for bone age if clinically indicated.

## STEP 2 — Rule In / Rule Out
Assess Tanner stage progression and laboratory markers (LH, FSH, estradiol/testosterone). If no Tanner advancement and LH/FSH are at prepubertal levels with sex steroids suppressed → Rule In (adequate suppression). Otherwise → Rule Out (inadequate suppression).

## STEP 3 — Classify or Stratify
For adequate suppression, classify as stable and continue routine monitoring; for inadequate suppression, classify as non‑suppressed and trigger adherence evaluation and dose reassessment.

## STEP 4 — Decide
If stable: maintain current GnRH agonist dose and follow‑up schedule. If non‑suppressed: verify adherence, consider dose increase, investigate causes (e.g., drug interactions, metabolism), and repeat assessment in 1–3 months.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely on Tanner stages alone without corroborating LH/FSH and sex steroid levels; do not omit vitamin D assessment in patients with limited sun exposure or malabsorption; avoid delaying bone density monitoring beyond 2‑year intervals in those with risk factors for osteoporosis; do not overlook psychosocial stressors that may affect medication adherence; never adjust GnRH agonist dose based solely on symptomatic changes without laboratory confirmation.

## Concrete Clinical Example
A 13‑year‑old transgender female starts leuprolide 3.75 mg SC monthly. At 4‑month visit, Tanner breast stage remains G2, LH is 0.2 IU/L, estradiol is 5 pg/mL. Assessment rules in adequate suppression; she continues the same dose with repeat labs and Tanner staging in 3 months.

**Source:** Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, https://doi.org/10.1210/jc.2017-01658